Literature DB >> 21134759

Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.

Comfort A Boateng1, Suresh V K Eyunni, Xue Y Zhu, Jagan R Etukala, Barbara A Bricker, M K Ashfaq, Melissa R Jacob, Shabana I Khan, Larry A Walker, Seth Y Ablordeppey.   

Abstract

Substitution around 5-methyl benzothieno[3,2-b]quinolinium (2) ring system was explored in order to identify positions of substitution that could improve its antifungal profile. The 3-methoxy (10b) was active against C. albicans, C. neoformans, and A. fumigatus and the 4-chloro (10f) analog showed moderate increases in anti-cryptococcal and anti-aspergillus activities. The effectiveness of 10b and 10f were validated in murine models of candidiasis and cryptococcosis, respectively. The efficacy of 10f in reducing brain cryptococcal infection and its observation in the brain of mice injected with this quaternary compound confirm the capacity of these compounds to cross the blood-brain barrier of mice. Overall, several of the chloro and methoxy substituted compounds showed significant improvements in activity against A. fumigatus, the fungal pathogen prevalent in patients receiving organ transplant. Opening the benzothiophene ring of 2 to form 1-(5-cyclohexylpentyl)-3-(phenylthio)quinolinium compound (3) resulted in the identification of several novel compounds with over 50-fold increases in potency (cf. 2) while retaining low cytotoxicities. Thus, compound 3 constitutes a new scaffold for development of drugs against opportunistic infections. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134759      PMCID: PMC3014419          DOI: 10.1016/j.bmc.2010.11.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  50 in total

1.  Probing the N-5 region of the indoloquinoline alkaloid, cryptolepine for anticryptococcal activity.

Authors:  S Y Ablordeppey; P Fan; A M Clark; A Nimrod
Journal:  Bioorg Med Chem       Date:  1999-02       Impact factor: 3.641

Review 2.  Protists as opportunistic pathogens: public health impact in the 1990s and beyond.

Authors:  J E Kaplan; J L Jones; C A Dykewicz
Journal:  J Eukaryot Microbiol       Date:  2000 Jan-Feb       Impact factor: 3.346

3.  A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols.

Authors:  Fuk Yee Kwong; Stephen L Buchwald
Journal:  Org Lett       Date:  2002-10-03       Impact factor: 6.005

4.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Authors:  M S Saag; R J Graybill; R A Larsen; P G Pappas; J R Perfect; W G Powderly; J D Sobel; W E Dismukes
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

5.  Substituted indoloquinolines as new antifungal agents.

Authors:  Seth Y Ablordeppey; Pingchen Fan; Shouming Li; Alice M Clark; Charles D Hufford
Journal:  Bioorg Med Chem       Date:  2002-05       Impact factor: 3.641

Review 6.  Emerging pathogens.

Authors:  J Pontón; R Rüchel; K V Clemons; D C Coleman; R Grillot; J Guarro; D Aldebert; P Ambroise-Thomas; J Cano; A J Carrillo-Muñoz; J Gené; C Pinel; D A Stevens; D J Sullivan
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

7.  A longitudinal study of lung transplant recipients infected with Aspergillus: genetic polymorphism of A fumigatus.

Authors:  F Symoens; S Bertout; M A Piens; J Burnod; F Renaud; N Nolard; F Chapuis; R Grillot
Journal:  J Heart Lung Transplant       Date:  2001-09       Impact factor: 10.247

8.  Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions.

Authors:  P Mwaba; J Mwansa; C Chintu; J Pobee; M Scarborough; S Portsmouth; A Zumla
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

Review 9.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

Review 10.  Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development.

Authors:  S Y Ablordeppey; P Fan; J H Ablordeppey; L Mardenborough
Journal:  Curr Med Chem       Date:  1999-12       Impact factor: 4.530

View more
  7 in total

1.  Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.

Authors:  Tryphon K Mazu; Jagan R Etukala; Xue Y Zhu; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2010-11-05       Impact factor: 3.641

2.  δ-Carbolines and their ring-opened analogs: synthesis and evaluation against fungal and bacterial opportunistic pathogens.

Authors:  Tryphon K Mazu; Jagan R Etukala; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey
Journal:  Eur J Med Chem       Date:  2011-03-17       Impact factor: 6.514

3.  Optimization of 3-(phenylthio)quinolinium compounds against opportunistic fungal pathogens.

Authors:  Comfort A Boateng; Xue Y Zhu; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey
Journal:  Eur J Med Chem       Date:  2011-02-23       Impact factor: 6.514

4.  Design, synthesis, and evaluations of antifungal activity of novel phenyl(2H-tetrazol-5-yl)methanamine derivatives.

Authors:  Amol B Salake; Aparna S Chothe; Shrikant S Nilewar; Madhavi Khilare; Rutuja S Meshram; Abhishek A Pandey; M K Kathiravan
Journal:  J Chem Biol       Date:  2013-09-12

Review 5.  The Mechanistic Targets of Antifungal Agents: An Overview.

Authors:  Tryphon K Mazu; Barbara A Bricker; Hernan Flores-Rozas; Seth Y Ablordeppey
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

6.  Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.

Authors:  Sidney Bolden; Xue Y Zhu; Jagan R Etukala; Comfort Boateng; Tryphon Mazu; Hernan Flores-Rozas; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey
Journal:  Eur J Med Chem       Date:  2013-10-05       Impact factor: 6.514

7.  CoMFA studies and in vitro evaluation of some 3-substituted benzylthio quinolinium salts as anticryptococcal agents.

Authors:  Sidney Bolden; Comfort A Boateng; Xue Y Zhu; Jagan R Etukala; Suresh K Eyunni; Melissa R Jacob; Shabana I Khan; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2013-09-03       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.